$2.02
+0.08 (+4.12%)
Open$1.98
Previous Close$1.94
Day High$2.06
Day Low$1.92
52W High$3.85
52W Low$1.56
Volume—
Avg Volume32.2K
Market Cap86.39M
P/E Ratio—
EPS$-0.66
SectorBiotechnology
Analyst Ratings
Strong Buy
10 analysts
Price Target
+1,577.7% upside
Current
$2.02
$2.02
Target
$33.89
$33.89
$29.33
$33.89 avg
$54.04
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 72.0K | 107.6K | 14.53M |
| Net Income | -28,370,376 | -38,143,618 | -1,603,701 |
| Profit Margin | -39,417.3% | -37,446.4% | -11.0% |
| EBITDA | -31,601,694 | -44,848,534 | -1,702,906 |
| Free Cash Flow | — | — | -884,905 |
| Rev Growth | -33.1% | -33.1% | +22.5% |
| Debt/Equity | — | — | 0.67 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $294.45 | -0.18% | 49.3 | 509.50B |
| AMGN | Amgen Inc | $467.06 | -0.22% | 26.5 | 248.84B |
| GILD | Gilead Sciences Inc | $167.95 | -1.05% | — | 208.28B |
| VRTX | Vertex Pharmaceuticals Inc | $542.62 | -0.81% | 34.5 | 137.12B |
| REGN | Regeneron Pharmaceuticals | $951.19 | -0.86% | 19.4 | 93.39B |
| ALNY | Alnylam Pharmaceuticals Inc | $156.65 | -2.00% | 7.7 | 20.98B |